AGM 1470

Drug Profile

AGM 1470

Alternative Names: TNP 470

Latest Information Update: 25 Nov 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Developer EntreMed; Takeda; TAP Pharmaceutical Products
  • Class
  • Mechanism of Action Aminopeptidase inhibitors; Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bladder cancer; Breast cancer; Cancer; Cervical cancer; Kaposi's sarcoma; Leukaemia; Lymphoma; Renal cancer

Most Recent Events

  • 25 Nov 2002 Discontinued - Phase-I for Cervical cancer in USA (IV-infusion)
  • 25 Nov 2002 Discontinued - Phase-I for Leukaemia in USA (unspecified route)
  • 25 Nov 2002 Discontinued - Phase-I for Lymphoma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top